Wie Big Data bei Patienten mit Prostatakrebs helfen können
Read moreWie Big Data bei Patienten mit Prostatakrebs helfen können Innovative Medicines Initiative genehmigt 12 Millionen Euro umfassendes, öffentlich-privates Forschungsprojekt zur Verbesserung der Betreuung von Patienten mit Prostatakrebs. Die Innovative Medicines Initiative (IMI) hat PIONEER genehmigt. Dabei handelt es sich...
We need you – Patient involvement is vital to the success of PIONEER
Read moreA critical requirement of the PIONEER project is to agree on and prioritise the most important questions in Prostate cancer diagnosis and treatment that need answered for the next generation. The EAU Prostate Cancer Guideline Panel and other experts have...
Cómo el Big Data (Macrodatos) puede ayudar a los pacientes con cáncer de próstata
Read moreCómo el Big Data (Macrodatos) puede ayudar a los pacientes con cáncer de próstata La Innovative Medicines Initiative (IMI) aprueba un proyecto de investigación público-privado de 12 millones de euros para mejorar la atención de los pacientes con cáncer...
Using #RWD to fill the knowledge gap
Read moreCarlos Moedas, Commissioner on Research, Science and Innovation of the European Commission tweeted: “Using #RWD to fill the knowledge gap: clinical trials & clinical practice & providing insights into disease patterns for effectiveness of health interventions is now reality thanks to...
How big data can help Prostate Cancer patients
Read morePress Release: How big data can help Prostate Cancer patients Innovative Medicines Initiative approves € 12 million public-private research project for improved care of prostate cancer patients. The Innovative Medicines Initiative (IMI) has approved PIONEER, a brand new five-year...
Contact us here
PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
